The Role of PPARγ in Helicobacter pylori Infection and Gastric Carcinogenesis

Jong-Min Lee, Sung Soo Kim, and Young-Seok Cho

Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu 480717, Republic of Korea

Correspondence should be addressed to Young-Seok Cho, yscho@catholic.ac.kr

Received 29 May 2012; Accepted 16 July 2012

Academic Editor: Valerio Pazienza

Copyright © 2012 Jong-Min Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear receptor that is important in many physiological and pathological processes, such as lipid metabolism, insulin sensitivity, inflammation, cell proliferation, and carcinogenesis. Several studies have shown that PPARγ plays an important role in gastric mucosal injury due to Helicobacter pylori (H. pylori). As H. pylori infection is the main etiologic factor in chronic gastritis and gastric cancer, understanding of the potential roles of PPARγ in H. pylori infection may lead to the development of a therapeutic target. In this paper, the authors discuss the current knowledge on the role of PPARγ in H. pylori infection and its related gastric carcinogenesis.

1. Introduction

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors and members of the nuclear hormone receptor superfamily. To date, three isoforms of PPARs (PPARα, PPARδ/β, and PPARγ) have been identified in mammals. PPAR forms a heterodimer with its preferential binding partner—retinoid X receptor (RXR). The function of PPAR/RXR heterodimer depends on its interactions with cofactor complexes (coactivators or corepressors). After activation by ligand, the PPAR/RXR heterodimer binds to specific DNA response elements called peroxisome proliferator response elements (PPREs) of the target genes. This results in transcription regulation of these genes (Figure 1) [1]. PPARs play a significant role in regulation of fatty acid oxidation and glucose utilization [2]. PPARγ was originally identified as a differentiation transcription factor for adipose tissue [3]. In addition, PPARγ is involved in the control of inflammation and glucose metabolism and participates in the processes of cellular proliferation, differentiation, and apoptosis [4]. Natural ligands for PPARγ are 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) and various polyunsaturated fatty acids [5, 6]. The insulin sensitizing thiazolidinediones, which are selective ligands of the nuclear transcription factor PPARγ, were the first drugs used to treat insulin resistance in patients with type II diabetes [7]. Helicobacter pylori (H. pylori) infection is the main etiologic agent in gastric inflammation, and longstanding infection with this organism is linked to gastric cancer [8]. Based on epidemiological studies, the risk of gastric cancer conferred by H. pylori has been estimated to be 75% [9]. Although the mechanism of H. pylori-induced carcinogenesis is still being investigated, inflammation is the strongest risk factor in the carcinogenic process [10], because it affects host responses such as epithelial cell proliferation and apoptosis [9]. PPARγ may be involved in the regulation of gene expression associated with inflammation and cancer. This paper reviews current knowledge of the role of PPARγ in H. pylori infection and its related gastric carcinogenesis.

2. PPARγ Expression in H. pylori Infection

PPARγ is predominantly expressed in adipose tissue, intestinal epithelium, monocytes and macrophages, the retina, skeletal muscle, and lymphoid organs [1]. Braissant et al. demonstrated PPARγ expression in the adult rat gastric mucosa by in situ hybridization and immunohistochemistry.
Several studies have found that PPARγ expression increases during *H. pylori* infection [12–14]. First, Konturek et al. demonstrated that PPARγ gene and protein expression were significantly higher in the gastric mucosa of *H. pylori*-positive gastric cancer patients than in *H. pylori*-negative healthy controls [12]. In addition, *H. pylori* eradication significantly reduced PPARγ expression. We demonstrated previously that PPARγ expression, identified by immunohistochemistry, was mostly detected in the nucleus of the foveolar epithelial cells in gastric mucosa and the intensity of PPARγ expression was significantly higher in the 18 patients with *H. pylori*-associated chronic gastritis than in the 21 *H. pylori*-negative patients (Figure 2) [13]. However, there was no correlation between the numbers of neutrophils and PPARγ expression in the two groups. Haruna et al. reported results similar to ours [14]. In this study, cyclooxygenase-2 (COX-2) and PPARγ mRNA expression in the gastric mucosa of children were found to be increased with *H. pylori* infection. The expression of COX-2, which plays an important role in inflammation, carcinogenesis, and development, is regulated by a negative feedback loop mediated through PPARγ [15]. Overexpression of both PPARγ and COX-2 was detected in the gastric mucosa of Mongolian gerbils infected with *H. pylori* [16]. Taking these findings together, enhanced PPARγ expression in gastric mucosa infected with *H. pylori* may have anti-inflammatory and cytoprotective effects.

### 3. The Role of PPARγ Activation in *H. pylori* Infection

Several studies have demonstrated that PPARγ has an overall anti-inflammatory effect [2, 17]. Molecular mechanisms include inhibition of signaling pathways regulating expression of proinflammatory genes (e.g., nuclear factor (NF)-κB) and stress-kinase pathways [17]. Gupta et al. demonstrated that PPARγ activation suppresses *H. pylori*-induced apoptosis in gastric epithelial cells and that this effect is mediated by direct inhibition of *H. pylori*-induced NF-κB activation [18]. *H. pylori* lipopolysaccharide (LPS), a component of the outer membrane, is a potent virulence factor for mucosal inflammatory changes, and its mechanism is mediated by increased proinflammatory cytokine production, excessive nitric oxide (NO) and PG generation, and epithelial cell apoptosis [19, 20]. B. L. Slomiany and A. Slomiany reported that PPARγ activation by ciglitazone inhibits gastric mucosal inflammation and that this effect is mediated by reduced apoptosis, mucosal PGE2 generation, expression of COX-2, and inducible nitric oxide synthase (NOS-2) [20]. In addition, ciglitazone impedes the inhibition of *H. pylori* LPS on gastric mucin synthesis, an effect likely dependent on the activation of the extracellular signal-related kinase (ERK) pathway by phosphatidylinositol 3-kinase (PI3K) [21]. These findings suggest that PPARγ activation may provide therapeutic benefits in *H. pylori*-associated gastric inflammation.

The transactivation of epidermal growth factor receptor (EGFR) is strongly linked to *H. pylori* infection, gastric epithelial hyperplasia, and gastric atrophy [10]. It depends on genes in the cag pathogenicity island, secreted proteins, and host factors such as TLR4 and NOD1 [22]. The biological responses to EGFR transactivation include increased proliferation, reduced apoptosis, altered cell polarity, and enhanced migration [10]. Although the underlying mechanism involved in the differential activation by ciglitazone of the EGFR/Erk mitogen activated protein kinases (MAPK) pathway is not well understood, this effect can be mediated by activation of Erk, an event requiring Src-kinase-dependent EGFR transactivation [23]. Ciglitazone has been shown to suppress *H. pylori* LPS inhibition of gastric mucin synthesis mediated by Src-kinase-dependent EGFR transactivation [24].

---

**Figure 1:** A basic mechanism of PPAR signaling. Following ligand binding, PPAR forms a heterodimer with RXR, which binds to the PPRE of target genes and regulates the transcription of these genes.
4. The Role of PPARγ in H. pylori-Related Gastric Carcinogenesis

Although the incidence of gastric adenocarcinoma is decreasing, it remains the second most common cause of cancer-related mortality worldwide [25]. There are large variations in the incidence and death rates among racial and ethnic groups, and the gastric cancer incidence and death rate are twice as high as in Asian American/Pacific islanders compared with Caucasians, reflecting an increased prevalence of chronic *H. pylori* infection [26]. Although gastric cancer treatments are continuously improving, the prognosis for this disease is poor and the survival rate is less than 40% even after curative resection and adjuvant chemotherapy [27].

Although the involvement of PPARγ in the development of cancer in various tissues remains controversial, PPARγ activation has antitumorigenic effects due to its antiproliferative and prodifferentiation activities [1]. Several *in vitro* studies have found that PPARγ activation results in cell cycle arrest and/or apoptosis of gastric cancer cells [28–32]. First, Takahashi et al. demonstrated that a human gastric cancer cell line, MKN45, expressed PPARγ mRNA and protein, and that PPARγ activation inhibited cell growth and induced apoptosis in gastric cancer cells [28]. Sato et al. used immunohistochemistry to show that the PPARγ protein is expressed in surgically resected specimens from well-, moderately, and poorly differentiated gastric adenocarcinomas as well as in noncancerous gastric mucosa with intestinal metaplasia [29]. The results of our study of PPARγ protein expression in gastric adenocarcinoma and normal mucosa with intestinal metaplasia adjacent to cancer were consistent with Sato’s results (Figure 2) [13]. However, recent studies have reported that redistribution of PPARγ expression occurs in human gastric adenocarcinoma [33–35]. The immunohistochemical staining pattern of PPARγ is nuclear in the normal gastric mucosa but primarily cytoplasmic in intestinal metaplasia (IM) [33]. The high cytoplasmic-to-nuclear expression ratio of PPARγ decreases as the differentiation stage changes from IM to adenoma, and to well-, moderately-, and poorly-differentiated cancers. PPARγ is expressed primarily in the nucleus in metastatic gastric cancer [34]. Burgermeister et al. demonstrated that the molecular mechanisms of PPARγ redistribution include interaction with Ras/mitogen activated protein kinases (MAPKs) such as caveolin-1 (Cav1) and docking protein 1 (Dok1) [35].

The inhibitory effect of PPARγ on gastric cancer may be attributed to various mechanisms. Ligand-induced activation of PPARγ was found to inhibit c-MET (an important protooncogene-encoding receptor for hepatocyte growth factor) [36] and expression of cyclin D1 [37] and COX-2 [31], induce expression of p27 [38], p21 [32], and p53 [39], and suppress gastrin (a potent cancer cell growth promoting...
factor) [40]. An in vivo animal study determined that heterozygous (PPARγ+/−) knockout mice were more susceptible to N-methyl-N-nitrosourea-induced gastric carcinoma than homozygotes (PPARγ+/+), but troglitazone only reduced the incidence of gastric cancer in homozygotes [41].

Konturek et al. reported that expression of tissue PPARγ, tissue levels of proinflammatory cytokines (IL-1β and IL-8), and plasma gastrin concentrations were significantly higher in H. pylori-positive gastric cancer compared to H. pylori-negative controls, but H. pylori eradication reduced these parameters [12]. These findings suggest that these parameters could be implicated in H. pylori-related gastric carcinogenesis. An in vitro study found that H. pylori infection downregulates the expression of p27 in gastric epithelial cells even in the absence of inflammation [42]. Reduced expression of p27 is found in H. pylori-associated intestinal metaplasia and H. pylori eradication reverses the aberrant expression of p27 [43]. Low p27 protein expression has been reported to be associated with increased expression of p27-specific F-box protein Skp2 and H. pylori eradication reverses the aberrant expression of p27 and Skp2 protein [44]. However, p27 and Skp2 mRNA levels were unaffected by H. pylori eradication, suggesting that H. pylori may influence cell cycle progression and carcinogenesis post-translational effects on specific gene expression. We have shown that rosiglitazone inhibited the growth of H. pylori-infected gastric epithelial cells [45]. These effects of rosiglitazone were associated with decreased Skp2 expression, thereby promoting p27 accumulation in H. pylori-infected gastric epithelial cells.

5. PPARγ Polymorphism in H. pylori-Related Gastric Carcinogenesis

A common PPARγ polymorphism, a C to G substitution in exon B, results in a proline to alanine exchange at codon 12 (Pro12Ala) [46]. Functionally, this Ala variant has been reported to show decreased binding to the response element and a lower capacity for activating target genes [47]. PPARγ polymorphism (Pro12Ala) has been found to be associated with various diseases including type II diabetes, cardiovascular disease, and several types of cancer [48]. Pro12Ala polymorphism lowers the risk of diseases in colorectal cancer and type II diabetes [49]. These results could be partly explained by the etiological link between type II diabetes and colorectal cancer. On the contrary, several studies have demonstrated that the Pro12Ala polymorphism is associated with the high risk of gastric adenocarcinoma [48, 50–53]. Liao et al. reported that the carriage of G phenotype or Ala allele in codon 12 of PPARγ was associated with a 2.5-fold increase in the risk of noncardia gastric cancer in Chinese, and that the risk was higher when this polymorphism was combined with H. pylori infection [50]. A recent meta-analysis suggested that carriers of Pro12Ala have a 2.31-fold (95% CI = 1.59–3.36, \( P_{heterogeneity} = 0.941 \)) increased gastric cancer risk [48]. Considering that PPARγ activation inhibits the growth of gastric cancer cells, these results suggest that gastric carcinogenesis may have a different genetic background than colorectal carcinogenesis.

The role of Pro12Ala polymorphism in peptic ulcer disease remains controversial. Prasad et al. showed that patients with Pro12Ala polymorphism were susceptible to peptic ulcer disease in the presence of H. pylori infection [52]. Meanwhile, Bazargani et al. found no significant increase in the risk of peptic ulcer formation among patients with Pro12Ala polymorphism [53]. This discrepancy may be due to the role of other bacterial virulence factors and/or host factors.

6. Conclusions

In this paper, we focused on the role of PPARγ in H. pylori infection and its related gastric carcinogenesis. PPARγ suppresses inflammation in H. pylori infection and tumor growth in gastric cancer. Emerging evidence indicates that mutations in PPARγ may play a crucial role in the development of noncardia gastric cancer in H. pylori-infected patients. Therefore, further studies are needed to investigate modulation of PPARγ as an effective therapy for chemoprevention and treatment of inflammation in H. pylori infection and gastric cancer.

Acknowledgment

This work was supported, in part, by a National Research Foundation of Korea (NRF) grant funded by the Ministry of Education, Science, and Technology (2010-0023295).

References

[1] L. Michalik, B. Desvergne, and W. Wahli, “Peroxisome-proliferator-activated receptors and cancers: complex stories,” Nature Reviews Cancer, vol. 4, no. 1, pp. 61–70, 2004.
[2] S. Kersten, B. Desvergne, and W. Wahli, “Roles of PPARs in health and disease,” Nature, vol. 405, no. 6785, pp. 421–424, 2000.
[3] P. Tontonoz, E. Hu, and B. M. Spiegelman, “Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor,” Cell, vol. 79, no. 7, pp. 1147–1156, 1994.
[4] P. Delerive, J. C. Fruchtart, and B. Staelens, “Peroxisome proliferator-activated receptors in inflammation control,” Journal of Endocrinology, vol. 169, no. 3, pp. 453–459, 2001.
[5] B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, “15-Deoxy-D12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ,” Cell, vol. 83, no. 5, pp. 803–812, 1995.
[6] S. A. Kliwer, J. M. Lenhard, T. M. Willson, I. Patel, D. C. Morris, and J. M. Lehmann, “A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation,” Cell, vol. 83, no. 5, pp. 813–819, 1995.
[7] J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliwer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ),” The Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995.
[8] R. M. Peek Jr. and M. J. Blaser, “Helicobacter pylori and gastrointestinal tract adenocarcinomas,” Nature Reviews Cancer, vol. 2, no. 1, pp. 28–37, 2002.
[9] V. Herrera and J. Parsonnet, “Helicobacter pylori and gastric adenocarcinoma,” Clinical Microbiology and Infection, vol. 15, no. 11, pp. 971–976, 2009.

[10] D. B. Polk and R. M. Peek Jr., “Helicobacter pylori: gastric cancer and beyond,” Nature Reviews Cancer, vol. 10, no. 6, pp. 403–414, 2010.

[11] O. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996.

[12] P. C. Konturek, J. Kania, V. Kukharsky et al., “Implication of peroxisome proliferator-activated receptor γ and proinflammatory cytokines in gastric carcinogenesis: link to Helicobacter pylori infection,” Journal of Pharmacological Sciences, vol. 96, no. 2, pp. 134–143, 2004.

[13] S. H. Son, H. K. Kim, J. S. Ji et al., “Expression of peroxisome proliferator-activated receptor (PPAR) gamma in Helicobacter pylori-infected gastric epithelium,” The Korean Journal of Gastroenterology, vol. 49, no. 2, pp. 72–78, 2007, in Korean.

[14] H. Haruna, T. Shimizu, Y. Ohtsuka et al., “Expression of COX-1, COX-2, and PPAR-γ in the gastric mucosa of children with Helicobacter pylori infection,” Pediatrics International, vol. 50, no. 1, pp. 1–6, 2008.

[15] H. Inoue, T. Tanabe, and K. Umesono, “Feedback control of cyclooxygenase-2 expression through PPARγ,” The Journal of Biological Chemistry, vol. 275, no. 36, pp. 28028–28032, 2000.

[16] P. C. Konturek, J. Kania, I. W. Konturek, A. Nikiforuk, S. J. Konturek, and E. G. Hahn, “H. pylori infection, atrophic gastritis, cytokines, gastrin, COX-2, PPAR-γ and impaired apoptosis in gastric carcinogenesis,” Medical Science Monitor, vol. 9, no. 7, pp. SR53–SR66, 2003.

[17] L. Dubuquoy, S. Dharrancy, S. Nutten, S. Pettersson, J. Aubert, and P. Desreumaux, “Role of peroxisome proliferator-activated receptor γ and retinoid X receptor heterodimer in hepatogastroenterological diseases,” The Lancet, vol. 360, no. 9343, pp. 1410–1418, 2002.

[18] R. A. Gupta, D. B. Polk, U. Krishna et al., “Activation of peroxisome proliferator-activated receptor γ suppresses nuclear factor kB-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells,” The Journal of Biological Chemistry, vol. 276, no. 30, pp. 31059–31066, 2001.

[19] J. Piotrowski, H. Piotrowski, D. Skrodzka, A. Slomiany, and B. L. Slomiany, “Induction of acute gastritis and epithelial apoptosis by Helicobacter pylori lipopolysaccharide,” Scandinavian Journal of Gastroenterology, vol. 32, no. 3, pp. 203–211, 1997.

[20] B. L. Slomiany and A. Slomiany, “Suppression of gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide by peroxisome proliferator-activated receptor γ activation,” IUBMB Life, vol. 53, no. 6, pp. 303–308, 2002.

[21] B. L. Slomiany and A. Slomiany, “Impedance of Helicobacter pylori lipopolysaccharide interference with gastric mucin synthesis by peroxisome proliferator-activated receptor γ activation involves phosphatidylinositol 3-kinase/ERK pathway,” IUBMB Life, vol. 55, no. 2, pp. 97–102, 2003.

[22] S. Basu, S. K. Pathak, G. Chatterjee, S. Pathak, J. Basu, and M. Kundu, “Helicobacter pylori protein HP0175 transactivates epidermal growth factor receptor through TLR4 in gastric epithelial cells,” The Journal of Biological Chemistry, vol. 283, no. 47, pp. 32369–32376, 2008.

[23] O. S. Gardner, B. J. Dewar, H. S. Earp, J. M. Samet, and L. M. Graves, “Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation,” The Journal of Biological Chemistry, vol. 278, no. 47, pp. 46261–46269, 2003.

[24] B. L. Slomiany and A. Slomiany, “Role of epidermal growth factor receptor transactivation in PPARγ-dependent suppression of Helicobacter pylori interference with gastric mucin synthesis,” Inflammopharmacology, vol. 12, no. 2, pp. 177–188, 2004.

[25] K. D. Crew and A. I. Neugut, “Epidemiology of gastric cancer,” World Journal of Gastroenterology, vol. 12, no. 3, pp. 354–362, 2006.

[26] A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA: A Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010.

[27] J. S. Macdonald, S. R. Smalley, J. Benedetti et al., “Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction,” The New England Journal of Medicine, vol. 345, no. 10, pp. 725–730, 2001.

[28] N. Takahashi, T. Okumura, W. Motomura, Y. Fujimoto, I. Kawabata, and Y. Kohgo, “Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells,” FEBS Letters, vol. 455, no. 1–2, pp. 135–139, 1999.

[29] H. Sato, S. Ishihara, K. Kawashima et al., “Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists,” British Journal of Cancer, vol. 83, no. 10, pp. 1394–1400, 2000.

[30] Y.-X. Chen, X.-Y. Zhong, Y.-F. Qin, W. Bingle, and L.-Z. He, “15d-PGJ2 inhibits cell growth and induces apoptosis of MCG-803 human gastric cancer cell line,” World Journal of Gastroenterology, vol. 9, no. 10, pp. 2149–2153, 2003.

[31] W. K. Leung, A. H. C. Bai, V. Y. W. Chan et al., “Effect of peroxisome proliferator activated receptor γ ligands on growth and gene expression profiles of gastric cancer cells,” Gut, vol. 53, no. 3, pp. 331–338, 2004.

[32] C. W. Cheon, D. H. Kim, D. H. Kim, Y. H. Cho, and J. H. Kim, “Effects of cigitazone and troglitazone on the proliferation of human stomach cancer cells,” World Journal of Gastroenterology, vol. 15, no. 3, pp. 310–320, 2009.

[33] S. Nomura, A. Nakajima, S. Ishimine, N. Matsushashi, T. Kadowaki, and M. Kaminishi, “Differential expression of peroxisome proliferator-activated receptor in histologically different human gastric cancer tissues,” Journal of Experimental and Clinical Cancer Research, vol. 25, no. 3, pp. 443–448, 2006.

[34] Q. He, J. Chen, H.-L. Lin, P.-J. Hu, and M.-H. Chen, “Expression of peroxisome proliferator-activated receptor γ, E-cadherin and matrix metalloproteinases-2 in gastric carcinoma and lymph node metastases,” Chinese Medical Journal, vol. 120, no. 17, pp. 1498–1504, 2007.

[35] E. Burgermeister, T. Friedrich, I. Hikova et al., “The Ras inhibitors caveolin-1 and docking protein 1 activate peroxisome proliferator-activated receptor γ through spatial relocalization at helix 7 of its ligand-binding domain,” Molecular and Cellular Biology, vol. 31, no. 16, pp. 3497–3510, 2011.

[36] S. Kitamura, Y. Miyazaki, S. Hiraoaka et al., “PPARγ inhibits the expression of c-MET in human gastric cancer cells through the suppression of Ets,” Biochemical and Biophysical Research Communications, vol. 265, no. 2, pp. 453–456, 1999.

[37] K. Yoshida, K. Tanabe, D. Fujii, N. Oue, W. Yasui, and T. Toge, “Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-γ in gastric carcinoma cells,” Anticancer Research, vol. 23, no. 1, pp. 267–273, 2003.
[38] S. Takeuchi, T. Okumura, W. Motomura, M. Nagamine, N. Takahashi, and Y. Kohgo, "Troglitazone induces G1 arrest by p27^Kip1 induction that is mediated by inhibition of proteasome in human gastric cancer cells," *Japanese Journal of Cancer Research*, vol. 93, no. 7, pp. 774–782, 2002.

[39] M. Nagamine, T. Okumura, S. Tanno et al., "PPARγ ligand-induced apoptosis through a p53-dependent mechanism in human gastric cancer cells," *Cancer Science*, vol. 94, no. 4, pp. 338–343, 2003.

[40] P. C. Konturek, J. Kania, V. Kukharsky, S. Ocker, E. G. Hahn, and S. J. Konturek, "Influence of gastrin on the expression of cyclooxygenase-2, hepatocyte growth factor and apoptosis-related proteins in gastric epithelial cells," *Journal of Physiology and Pharmacology*, vol. 54, no. 1, pp. 17–32, 2003.

[41] J. Lu, K. Imamura, S. Nomura et al., "Chemopreventive effect of peroxisome proliferator-activated receptor γ on gastric carcinogenesis in mice," *Cancer Research*, vol. 65, no. 11, pp. 4769–4774, 2005.

[42] H. Shirin, E. M. Sordillo, T. K. Kolevska et al., "Chronic *Helicobacter pylori* infection induces an apoptosis-resistant phenotype associated with decreased expression of p27^{kip1}," *Infection and Immunity*, vol. 68, no. 9, pp. 5321–5328, 2000.

[43] J. Yu, W. K. Leung, E. K. W. Ng et al., "Effect of *Helicobacter pylori* eradication on expression of cyclin D2 and p27 in gastric intestinal metaplasia," *Alimentary Pharmacology and Therapeutics*, vol. 15, no. 9, pp. 1505–1511, 2001.

[44] S. S. Kim, P. Meitner, T. A. Konkin, Y. S. Cho, M. B. Resnick, and S. F. Moss, "Altered expression of Skp2, c-Myc and p27 proteins but not mRNA after *H. pylori* eradication in chronic gastritis," *Modern Pathology*, vol. 19, no. 1, pp. 49–58, 2006.

[45] S. S. Kim, Y. S. Cho, H. K. Kim et al., "The effect of rosiglitazone on the cell proliferation and the expressions of p27 and skp2 in *Helicobacter pylori* infected human gastric epithelial cells," *The Korean Journal of Gastroenterology*, vol. 55, no. 4, pp. 225–231, 2010, in Korean.

[46] Y. Chung-Jen, B. A. Beamer, C. Negri et al., "Molecular scanning of the human peroxisome proliferator activated receptor γ (hPPARγ) gene in diabetic Caucasians: identification of a Pro12Ala PPARγ2 missense mutation," *Biochemical and Biophysical Research Communications*, vol. 241, no. 2, pp. 270–274, 1997.

[47] S. S. Deeb, L. Fajas, M. Nemoto et al., "A Pro12Ala substitution in PPARy2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity," *Nature Genetics*, vol. 20, no. 3, pp. 284–287, 1998.

[48] W. Xu, Y. Li, X. Wang et al., "PPARγ polymorphisms and cancer risk: a meta-analysis involving 32,138 subjects," *Oncology Reports*, vol. 24, no. 2, pp. 579–585, 2010.

[49] W. P. Koh, J. M. Yuan, D. Van Den Berg, S. A. Ingles, and M. C. Yu, "Peroxisome proliferator-activated receptor (PPAR) γ gene polymorphisms and colorectal cancer risk among Chinese in Singapore," *Carcinogenesis*, vol. 27, no. 9, pp. 1797–1802, 2006.

[50] S.-Y. Liao, Z.-R. Zeng, W. K. Leung et al., "Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism, *Helicobacter pylori* infection and non-cardia gastric carcinoma in Chinese," *Alimentary Pharmacology and Therapeutics*, vol. 23, no. 2, pp. 289–294, 2006.

[51] T. Tahara, T. Arisawa, T. Shibata et al., "Influence of peroxisome proliferator-activated receptor (PPAR)γ Plo12Ala polymorphism as a shared risk marker for both gastric cancer and impaired fasting glucose (IFG) in Japanese," *Digestive Diseases and Sciences*, vol. 53, no. 3, pp. 614–621, 2008.

[52] K. N. Prasad, A. Saxena, U. C. Ghoshal, M. R. Bhagat, and N. Krishnani, "Analysis of Pro12Ala PPAR gamma polymorphism and *Helicobacter pylori* infection in gastric adenocarcinoma and peptic ulcer disease," *Annals of Oncology*, vol. 19, no. 7, pp. 1299–1303, 2008.

[53] A. Bazargani, S. S. Khoramrooz, E. Kamali-Sarvestani, S. A. Taghavi, and M. Saberifiroozi, "Association between peroxisome proliferator-activated receptor γ gene polymorphism (Pro12Ala) and *Helicobacter pylori* infection in gastric carcinogenesis," *Scandinavian Journal of Gastroenterology*, vol. 45, no. 10, pp. 1162–1167, 2010.